Hoping for A Christmas Miracle for All US Physicians

Imagine an end to the forced participation in the American Board of Medical Specialties (ABMS) trademarked Maintenance of Certification (MOC) program required by all US academic (and many non-academic) hospital systems in the United States. Ending the unproven MOC program’s constant threat of loss of employment because of failure to make a MOC payment to one of the 24 member boards of the ABMS, or because of failure to participate in their repeated online or in-person testing has seemed impossible.

Until now.

January 15, 2025 is the date set for oral arguments before the 7th Circuit Court of Appeals in Chicago in Lazarou v ABPN (No. 24-1994) antitrust case. If the judges rule favorably in the Plaintiffs’ favor, the complaint will finally go to discovery and jury trial. This case, if won, would set a precedent to legally challenge MOC for each of the other 23 member boards of the ABMS.

But all of us need to do our part. To put it bluntly, it will take a little bit of cash to help make this happen. About $11,000 more added to the GoFundMe page created for the legal efforts underway is needed for additional preparatory legal work. Depending on how many physicians give, that might be as little needed as $1 or $5 per doctor.

Please don’t turn away. Give now. Even the smallest donation can make a huge difference, Please help us bring this lengthy legal effort to fruition.

Thank you and

Merry Christmas and Happy Holidays.

Wes Fisher, MD

Latest Updates on MOC Antitrust Lawsuit Appeal

Following dismissal of their antitrust lawsuit against the American Board of Psychiatry and Neurology (ABPN) regarding Maintenance of Certification (MOC) in May 2024, Emily Elizabeth Lazarou, MD and Aafaque Akhter, MD appealed their case to  the United States Court of Appeals for the Seventh Circuit. What follows is an artificial intelligence-generated review of where that appeal stands, using an Adobe AI Assistant to simplify understanding of the arguments pleaded so far by both sides.


The issue statement in the appeal brief filed by the plaintiffs is:

“Whether the District Court erred in dismissing Plaintiffs’ tying claims when it found Plaintiffs failed to plausibly allege that Defendant-Appellee American Board of Psychiatry and Neurology’s (“ABPN”) maintenance of certification (“MOC”) product is a continuing medical education (“CME”) product.” ​

The main arguments presented by the plaintiffs are:

  1. MOC as a CME Product: The plaintiffs argue that the Maintenance of Certification (MOC) product offered by the American Board of Psychiatry and Neurology (ABPN) is a Continuing Medical Education (CME) product. ​ They claim that MOC contains educational content, provides CME credits for state licensure, and is not redundant of other CME requirements. ​
  2. Substitutability of MOC: The plaintiffs assert that MOC is a substitute for other CME products. ​ They argue that doctors use MOC to meet state CME licensure requirements, and that MOC provides CME credits directly through the AMA and is accepted by many states in place of CME requirements.
  3. Antitrust Standing: The plaintiffs claim they have antitrust standing because they are directly affected by the alleged tying arrangement. ​ They argue that the tying of MOC to initial certification by ABPN restricts competition in the CME market, forcing doctors to purchase MOC instead of other CME products. ​
  4. Economic Impact: The plaintiffs allege that ABPN’s tying arrangement has led to a significant increase in MOC revenue and a decline in the number of CME providers, indicating a substantial foreclosure of competition in the CME market. ​
  5. Request for Leave to Amend: If the court finds that specific evidentiary details about individual state CME requirements should have been included in the complaint, the plaintiffs request leave to amend the complaint to provide such details. ​
  6. Reinstatement of Unjust Enrichment Claim: The plaintiffs argue that upon reinstatement of their Sherman Act claims, their unjust enrichment claim should also be reinstated, as it is related to the same set of facts and legal issues.

The American Board of Psychiatry and Neurology (ABPN) responded with several key arguments to support the dismissal of the plaintiffs’ case:

  1. Stare Decisis: ABPN argues that the doctrine of stare decisis, which mandates adherence to previous court decisions, forecloses this suit. ​ The case at hand is materially identical to the Siva v. American Board of Radiology case, which was dismissed by the Seventh Circuit. ​ Therefore, the same reasoning should apply, and the dismissal should be upheld. ​
  2. False Equivalence: ABPN contends that the plaintiffs’ legal theory is based on a logical fallacy of false equivalence. ​ The plaintiffs incorrectly equate the Maintenance of Certification (MOC) program with Continuing Medical Education (CME) products. ​ MOC is a comprehensive program with multiple requirements, not just a collection of CME credits. ​ Therefore, MOC cannot be considered a substitute for CME products. ​
  3. Lack of Substitution: ABPN argues that MOC is not a substitute for CMEs. ​ The plaintiffs fail to plausibly allege cross-price elasticity, which would show that MOC and CMEs are reasonably interchangeable in the minds of relevant consumers. ​ Additionally, MOC is not required for state licensure, and many states prohibit considering MOC for licensure maintenance. ​
  4. No Financial Interest in CME Products: ABPN highlights that it has no financial interest in any accredited CME products. ​ The MOC program requires diplomates to purchase CME products from other providers, and ABPN does not produce or have a financial stake in these products.
  5. Lack of Coercion or Force: ABPN asserts that the plaintiffs have not plausibly alleged actual coercion or force. ​ The adverse consequences of not maintaining board certification are imposed by third parties, such as hospitals and insurance companies, not by ABPN itself. ​ Therefore, there is no illegal tying. ​
  6. Non-Competitor in CME Market: ABPN argues that it is not a competitor in the CME market. ​ The plaintiffs’ own contentions that MOC is effectively useless and not valued by physicians confirm that MOC does not compete on the merits in the CME market. ​
  7. Denial of Leave to Amend: ABPN contends that the district court did not abuse its discretion in refusing to allow the plaintiffs to file a fourth complaint. ​ The plaintiffs had multiple opportunities to state a claim and failed to do so. ​ The district court provided a reasonable explanation for the dismissal with prejudice. ​

In summary, ABPN’s arguments focus on the application of stare decisis, the logical fallacy in the plaintiffs’ claims, the lack of substitution and financial interest, the absence of coercion, and the non-competitive nature of MOC in the CME market. ​ These points collectively support the dismissal of the plaintiffs’ case.


The subsequent reply brief by the Plaintiffs to ABPN’s arguments explains that the doctrine of stare decisis is inapplicable in this case because the Second Amended Complaint (SAC) contains substantial new factual allegations that address specific concerns raised in the prior decision, Siva v. American Board of Radiology. ​ The brief argues that stare decisis applies only to legal determinations made in prior precedential opinions and does not apply to issues of fact or new information that were not part of the previous decision. ​ The brief cites several cases to support this argument, emphasizing that stare decisis is limited to legal issues actually decided in a prior action and does not extend to different facts or new records. ​ The brief also distinguishes the current case from the Third Circuit’s non-precedential Kenney opinion, noting that the SAC includes new allegations not considered in Kenney and that Kenney’s analysis was contrary to the Seventh Circuit’s holding in Viamedia v Comcast (7th Cir 2020). ​

The reply brief outlines several new factual allegations included in the Second Amended Complaint (SAC) that address the concerns raised in the prior decision, Siva v. American Board of Radiology. ​ These new allegations are:

  1. Educational Content: The SAC alleges that Maintenance of Certification (MOC) has educational content, which was not sufficiently detailed in the previous complaint. ​
  2. CME Credit: The SAC includes allegations that doctors can earn Continuing Medical Education (CME) credits from MOC, which can be used for state licensure requirements. ​
  3. Non-Redundancy: The SAC asserts that MOC is not redundant of other CME requirements, addressing the concern that MOC simply imposes a redundant obligation to buy other CME products. ​
  4. Substitutability: The SAC provides detailed allegations showing that MOC is a substitute for other CME products, including that doctors view MOC and other CME products interchangeably and that MOC serves the same purpose as other CME products. ​
  5. Market Demand: The SAC includes allegations that MOC and other CME products are reasonably interchangeable in the minds of relevant consumers, permitting an inference of cross-price elasticity between MOC and other CME offerings. ​
  6. State Acceptance: The SAC details how many states accept MOC in full or partial satisfaction of CME requirements for licensure, and that MOC can be used to meet state CME requirements. ​
  7. Economic Impact: The SAC alleges that the number of accredited providers of continuing medical education has declined significantly since the advent of MOC, indicating a substantial foreclosure of competition in the CME market. ​

These new allegations aim to address the deficiencies identified in the Siva decision and provide a more robust basis for the plaintiffs’ claims. ​ The new factual allegations are significant for several reasons:

  1. Addressing Pleading Deficiencies: The new allegations directly address the deficiencies identified in the prior decision, Siva v. American Board of Radiology. ​ By including detailed facts about the educational content of MOC, the ability to earn CME credits from MOC, and the non-redundancy of MOC with other CME requirements, the plaintiffs aim to meet the pleading standards required to survive a motion to dismiss.
  2. Establishing Substitutability: The new allegations provide a basis for arguing that MOC is a substitute for other CME products. ​ This is crucial for establishing that MOC and other CME products are part of the same relevant product market, which is necessary for the plaintiffs’ tying claim. ​
  3. Demonstrating Market Impact: By alleging that MOC has led to a significant decline in the number of accredited CME providers and that MOC is accepted by many states for licensure requirements, the plaintiffs aim to show that MOC has a substantial impact on the CME market. This supports their argument that ABPN’s practices have anticompetitive effects. ​
  4. Countering Stare Decisis: The new factual allegations help to counter the defendant’s argument that the doctrine of stare decisis should apply. ​ By presenting new and specific facts that were not considered in the previous case, the plaintiffs argue that the current case is materially different and should not be bound by the prior decision. ​
  5. Supporting Economic Realities: The allegations about the economic necessity of certification for hospital privileges, insurance, and employment help to explain why ABPN’s conditioning of certification on the purchase of MOC constrains doctors’ choices. ​ This supports the plaintiffs’ claim of “forcing” in the context of an illegal tying arrangement. ​

Overall, the new factual allegations strengthen the plaintiffs’ case by providing a more detailed and robust foundation for their claims, addressing the concerns raised in the prior decision, and demonstrating the anticompetitive impact of ABPN’s practices. ​


The ABPN still has on opportunity to respond the plaintiff’s reply brief before the case goes to oral arguments.

According to the court docket, oral arguments will occur sometime after 12 Dec 2024 when the Plaintiff’s attorney is available. We hope to update US physicians when those arguments are scheduled.


Contributions to support these updates and the legal effort underway to end MOC’s stranglehold on US physicians are still being accepted. Please give generously to our ongoing GoFundMe campaign.

Challenging ABPN’s MOC Monopoly: Judge’s Decision and Potential Appeal

On May 13, 2024, Judge Jeremy C. Daniel  of the Seventh District Federal Court dismissed the Second Amended Complaint (SAC) in the Lazarou v American Board of Psychiatry and Neurology (1:19-cv-01614) anti-trust case regarding ABPN’s Maintenance of Certification (MOC) monopoly.  Despite the SAC demonstrating MOC’s interchangeability and substitution for CME, competitive disadvantage of physicians forced to purchase MOC products before they purchase CME products, a significant financial stake afforded to ABPN by MOC, and the market decline of CME products since MOC was instituted, the judge felt MOC and CME were NOT interchangeable and MOC and initial certification were NOT separate products, but one product, ABPN board certification. 

But the Seventh Circuit Court previously rejected ABPN’s post-tie argument about MOC’s “integration” with certification in Siva v Am Board of Radiology (7th Cir. 2022). (“In reaching the conclusion that certification and MOC were a single product in part because of the degree of ‘integration’ between the two, the district court improperly approached the analysis from a post-tie perspective.”)

Given this and the other evidence provided by the SAC, Judge Daniel’s opinion might collapse at the Appellate court level. Still, the ABPN will have the collective legal resources of the entire ACGME member organizations (AHA, AMA, ABMS, among others) at their disposal to defend the ABPN.

After reviewing the decision with their attorney’s, both Plaintiffs in the case against ABPN have decided to press forward and appeal Judge Daniel’s decision. That appeal should be filed by late August of this year.

Working US physicians are not quitters. We have worked hard for our right to work on behalf of patients who trust us with their lives. We don’t give up when the going gets tough and the clearly worded Second Amended Complaint is nullified by one judge who does not understand the financial, personal, and healthcare marketplace harms created by changing the once lifetime US board certification into time-limited, “continuous” board certification with MOC’s specialty-wide implementation in 1990.

Since its inception, the ABMS MOC program has not taught us how to keep up with our fields of medicine any better than self-selected ACCME-accredited CME. Instead, MOC has taught us that discrimination and strongman tactics against younger, more vulnerable physicians are fine, that conflicts of interest (both financial and political) are to be tolerated, and strongman tactics (like threats to employment to force payments to these unelected non-profit entities) are incredibly lucrative.

Now, more than ever, physicians must unite and act collectively to end the annual ABMS MOC extortion of working physicians. No individual or subspecialty organization will do this for us.

For the good of our profession and all those working physicians who come after us, please give generously to help support these the physician Plaintiffs trying to end the ABMS’s monopoly on Maintenance of Certification.

Wes Fisher, MD

Practicing Physicians of America

PBM: Unmask the Villains of Healthcare’s High Costs

Marion Mass, M.D. and Christina Dewey, M.D.

Would you like to lower healthcare costs, restore quality and improve choice? Yes? Then you MUST learn about Pharmacy Benefit Managers (PBMs).

If you look on the Fortune 500 top 12 companies, you will find three companies who own PBM. Dig deeper, and you’ll discover these companies are CVS  health, who owns the PBM CVS Caremark, United Healthcare who owns the PBM Optum Rx, and Cigna, who owns the PBM Express Scripts. These three PBM control 85% of the prescription drug market, and are the biggest revenue generators for their parent companies. 

For example, when the insurance company Cigna, purchased Express Scripts in 2019, their revenues tripled. Take a peek under the hood of CVS Health, and you will discover that CVS’s  PBM CVS Caremark is, to put it frankly, its prize cash cow, its biggest source of revenue.  Moo.  

Until recently, many Americans had no idea what a PBM was, and blamed insurance and pharma and physicians for the high cost of care. The truth is much more complicated, and those making the money don’t want you to pull the mask off the villain of high healthcare costs.  They aim to prevent  the Scooby Doo denouement and keep Americans from discovering the biggest, richest, most devious villains in the healthcare space are the PBM.

Some really important clues to why we should suspect that the PBM are villainous profiteers:

–    The PBM and insurance companies now own one another, and some, like the CVS Health empire, also own pharmacy chains

–    The PBM controls the pharmaceutical companies, by creating the formularies, aka the list of medications that the insurance companies will “cover”. Physicians play no part, nor have any say in  this choice.

–    The PBM can collect legalized kickbacks, called ‘rebates’ from pharmaceutical companies because the PBM were granted an exemption from the anti-kickback statute in 2003 by GW Bush’s HHS secretary. This anti-kickback exemption allows pharmaceutical companies to simply pay for placement on the formulary.  Americans are not necessarily getting the best medication, but the best med a legal bribe can buy.

–    There is no transparency for these kickbacks (aka rebates) but sources have revealed that in 2020, the total amount of kickbacks approached $200 BILLION (yes with a B).

–    PBM like CVS Caremark are now facing charges of preventing elderly Medicare patients, including those with End Stage Kidney Failure from access to affordable life sparing medications.

–    In multiple states, PBM have been found to be helping themselves to Medicaid money… not a small helping, either: In Ohio alone, the PBM subsidiary of Centene as well as CVS and Optum were pocketing $244million per year.

 

–    The big PBM that own pharmacies, like CVS are utilizing shady practices to put trusted Mom and Pop pharmacies out of business.    

 

–    In an NBC News exclusive with Cynthia McFadden, the PBM mail order pharmacies were found to be delivering ineffective medications.  One young pediatric patient with cystic fibrosis was hospitalized after wasting away because of medications delivered by PBM giant Express Scripts, whose agent pooh poohed the concerns of the patient’s mother.

Do you need to hear more? 

Yes, you need to understand who is granting more favors to the behemoth companies responsible for the maleficent behavior noted above.

Let’s look at several recent congressional bills in chronological order of passage. 

The Affordable Insulin Now Act was passed by the House and Lingers in the senate

Although those who support the bill  claim to have lowered the cost of insulin, Lloyd Dogget, a Texas Democrat correctly stated that the bill does not lower the cost of insulin by even a penny.  He’s correct.  It lowers the co-pay, but the uninsured, and those who pay insurance ( whether they be employer or independent purchaser)  will continue to pay the full bloated cost of insulin, 80% of which is flowing to the PBM via kickbacks and fees.  In other words, this bill simply ensures that the taxpayers keep paying the PBM in the form of kickbacks.

Worse yet, the bill grants a delay of the rebate rule for PBM.  The rebate rule was an Executive Order introduced in 2020 and demanded that the kickbacks (aka rebates) would flow to the patient at the point of sale and not the PBM and the insurers.  PBMs are continually telling Americans that they pass on the rebates, yet when the rebate rule was suggested, they have threatened to increase Medicare premiums as soon as the rule is enacted. 

Congress has discovered they can pull the entirely disingenuous accounting sleight of hand of delaying the rebate rule (in other words, allowing the PBM to keep collecting their kickbacks and not forcing them to pass on to patients) and thereby claiming that they are saving money by preventing Medicare premium increases. To put another way, the PBM’s and Insurers are playing Chicken with the rebate rule by threatening Medicare premium increases, and the Congress-people that delay the rebate rule are taking the bait.  I suppose that makes them lower than chickens in the game.  Perhaps they are simply chicken….. oh, never mind. Maybe they simply don’t understand.

The insulin Bill was not the first time Congress  delayed the rebate rule.  Apparently they did it in the infrastructure bill, too.  Howard Dean, a physician and former presidential candidate called them on it in Newsweek, even pointing out that the rebate rule was solid, and potentially the best thing to come from the Trump Presidency. 

Based on the above, we ought to let that insulin bill die and come up with a real way to lower insulin costs.

The recent Gun Bill Passed by the Senate and House and signed into law sneaked in a gift to PBMs.

Why on earth would a bill on guns contain another delay in the rebate rule, yet another gift to the PBM industry?  The same faulty accounting gimmick of using the rebate rule delay as a pay for.  Unbelievable.  Senators Chris Murphy, D-CT and John Cornyn, R-Tx are mum about who put the PBM poison pork into the gun bill.  Interestingly, Murphy’s top donor is the law firm that helps CVS negotiate mergers.  And Cornyn is a top taker from Vizient, a hospital Middleman Group Purchasing Organization.

Good news at last!  PBM reform in the Mental Health Package

Thankfully, some good news exists. .  Some colossally INCREDIBLE news:

HR 7666, the bipartisan mental health bill introduced by Frank Pallone, D-NJ, and Cathy McMorris Rogers –R, Wa passed the house this week with 400 yay votes.

Some of us were really yelling ‘Yay’ when we discovered splendid section 602, quietly added by Rep Michael Burgess (R-Tx), mandating   big time TRANSPARENCY for big PBM/Insurers with shocking penalties of $10K per day for non-compliance.

Requiring  PBM transparency will save $2BILLION/10 years, paying for the bill.  Billion with a ‘B’.  As Mental health and substance abuse medications are largely overpriced due to PBM kickbacks, this provision absolutely belongs in the bill.

Americans will receive  some wonderful services  with this bill for Mental Health and Substance Use Disorders. Full detail can be found in the bill,  but here is a screenshot of some of the high points

WE CANNOT STOP… we must make sure the mental health bill passes in the senate WITH PBM reform Intact

Please CALL and EMAIL  both of your US Senators ASAP, (find their numbers and email contact links  here ) and tell them to PASS  the Senate version of HR 7666 with the Burgess amendment to bring PBM transparency and accountability intact.  Ask  your friends to call.  Ask your neighbors to call. Ask everyone in your circle and beyond. Tell YOUR Senators you now know the PBMs are behind the ever increasing healthcare costs and it’s time for Congress  to listen to we the people and not the profiteering villainous Pharmacy Benefit Managers! 

Drs. Mass and Dewey are proud to be pediatricians for over 20 years each and fierce advocates for patients and physicians!

Dr. Mass, graduated from Duke Medical School and trained at Northwestern. She has practiced in the Philadelphia area. She’s a cofounder of Practicing Physicians of America And leadership in Free To Care .

Dr. Dewey attended Loyola University Stritch School of Medicine . She did a year of surgery internship then two years of pediatric surgery research before training in Pediatrics at University of Minnesota. She is founder and CEO of Peds Mama Doc and has published in multiple outlets

Speak on Trump’s Order on Price Transparency in Health Care by 1/29

PPA is encouraging that physicians and others comment to Health and Human Services regarding the Trump Administrations’ most recent Price transparency rule found here.

 This proposed rule complements a previous rule requiring hospitals to post their actual prices online and requiring insurers to disclose (in easy-to-understand format) the prices they now negotiate in secret with hospitals and other providers. The effect would be to enable patients to have some idea before they receive care of what they could end up owing to a provider after the care is delivered and the insurer has issued an Explanation of Benefits (EOB) showing what portion of the cost has been covered. This is a step toward pricing sanity in a more-competitive healthcare marketplace because it supports informed shopping by consumers of medical services. The intent is to enlist and boost the power of consumers in driving down prices.

It is crucial for physicians and patients to comment, as the insurance and hospital industry have come out in full force supporting the now hidden prices that have allowed these two industries to profit themselves while gouging Americans.   This is especially true of the most consolidated hospital systems and dominant insurance companies who use opacity combined with their respective market shares to continually drive prices up.  They simply have no incentive to lower prices. 

PPA’s full comments are below.  You are welcome to copy and paste them in part or whole.  When commenting, adding your personal story regarding how patients are hurt by opaque prices.  

For ease, you can consider copying and pasting a personalized form of these italicized comments: firmly support the current efforts to bring the prices of medical services and procedures into the open and to make those prices easily accessible to our patients—in short, to replace price opacity with price transparency.

Noting that in the proposed rule, HHS also requested comments regarding how to enact transparency of quality, I request transparency in the level of the training attained by those who deliver care, and full disclosure of conflicts of interests of any person or organization the government relies on to define or implement quality in health care.

SUBJECT: CMS-9915-P, Comment on the Proposed Rule Mandating Price Transparency

Ending price OPACITY in favor of price TRANSPARENCY is critical to driving down the costs of all forms of medical care in America.

Practicing Physicians of America (PPA)—a non-profit organization representing thousands of physicians, and a part of the Free-to-Care Coalition, now comprised of 37,000 physicians and 3 million citizens—declare their firm support for the proposed rule requiring insurers to reveal the prices they negotiate with all providers of medical care.

Why Transparency is So Sorely Needed

Each day, the thousands of physicians represented by PPA see the pain in the pocketbook of our patients. We see their foremost concern when they seek medical care. What will this cost?

We have observed our patients incurring higher out-of-pocket costs for health insurance (which ought NEVER to be confused with actual healthcare) that outpace their wage increases and threaten the financial viability of their households. 

More than ever before, the patients we treat in our offices are looking for an accessible, easy-to-understand way to shop for the medical services they need and to control their medical expenses. They would like also to see the exposure and defeat of the hidden forces that drive the relentless rise in premiums in response to excessive costs routinely obscured under the third-party payer system that has dominated American healthcare for close to 50 years and been an engine of our stratospheric rates of inflation in the cost of healthcare.

Price opacity, which has enabled forms of price gouging, has produced the environment we see today in which one in five Americans have had medical bills turned over to collection agencies.

This country desperately needs informed consumers of medical services who have choices at their disposal. Price opacity abets ignorance. Price transparency would vindicate the axiom of Francis Bacon: Nam et ipsa scientia potestas est. (Knowledge is power.) The informed consumer who is capable of making choices in a free marketplace that has been disciplined by competition is the only reliable force for driving down deductibles, premiums, and other costs. 

Do the lobbyists of the health insurance and corporate hospital industries resist calls for the end of opacity and the introduction of transparency? Of course they do. They’ll move heaven and earth to keep the good thing going that has fattened their coffers at the expense of the American patient. Those administrator-heavy industries drive inflation in healthcare by every means our current system has legitimized.

Consider the following.

For certain services and procedures provided on an inpatient basis, hospital charges grew by 42% over the eight-year period from 2007 to 2014.

Similarly, for hospital-based, outpatient care involving the same services and procedures, charges increased by 25%.

The charges for the same services and procedures provided by independent physicians grew by only 6% over the same eight-year period.

Those figures are drawn from a study of insurance claims data by the Health Care Cost Institute that has been the subject of reports in the last year.

Meanwhile, as the resources of the American consumer of medical care are relentlessly squeezed, the profitability of the health insurance industry is a picture of robust financial health

The health insurance and corporate hospital industries benefit from the price opacity that has become the sine qua non of the wildly inflationary, third-party payer system that has dominated the landscape of American healthcare for a half-century.

This scandalous gravy train operating under cover of law and public policy must be halted. Transparency is the brake to do the job. 

Those who enact national policy via regulation need to think FIRST of the needs of American patients and to tell the lobbyists of the health insurance and corporate hospital industries that they will no longer be permitted to be the dominating, decisive voices in the room.

On Quality

In inviting comment, the Departments have raised also the question of how Americans can shop on an informed basis for medical care of high quality that is affordable.

Yes, quality can be hard to define and quantify… although most people recognize it when they see it and can distinguish differences in quality when they experience them.

PPA offers this counsel. If the Departments are contemplating a forum of stakeholders to explore the question of quality in healthcare, it would be essential that any such forum be composed of the full range of stakeholders, most heavily represented by patients and the physicians who deal with them directly and personally.

When it comes to physicians, a “quality forum” should include not only physicians employed by corporations but also independent physicians.

When it comes to hospitals, a “quality forum” should include not only the urban, the regional, the large, and the corporate, but also the smaller, the rural, and the independent.

In addition, the representatives of stakeholders participating in any such forum on quality must be required to declare the interests they represent. The interest of the wider public, American patients—who seek to maintain their choices while simultaneously looking for relief from the high costs related to the medical care they receive and the insurance they carry as a hedge against catastrophic costs—  must be protected from the special and narrow interests that have greatly profited under the current inflationary, increasingly consolidated, increasingly corporatized system that has sprung up and flourished under a system of opacity.

“Quality” as a Function of the Practitioner’s Training 

As shown by surveys over the last decade, one measure for enhancing patients’ recognition of quality would be mandating transparency regarding the level of training acquired by medical practitioners. As the numbers of nurse practitioners and physician’s assistants have grown over a period that has seen some states allow nurse practitioners to “practice” as the functional equivalent of physicians, patients have experienced increasing confusion over who is delivering their care.

There is a vast gulf between the minimum 15,000 hours of clinical experience needed to become a physician and the 500 or 1,000 clinical shadowing hours needed to qualify as a nurse practitioner, or the 2,000 clinical hours required of a physician’s assistant. Given the obvious disparity in-depth and quality of training for these levels of medical practitioner, patients deserve to know the degree of training experienced by their caregivers, and they deserve the freedom to seek care from practitioners of their choosing.

Requiring hospitals and clinics to post prominently the levels of training of all practitioners is a simple step toward transparency. It will minimize confusion and strengthen the ability of the American patient to identify quality. 

Conclusion

Regarding Transparency. PPA firmly supports the current efforts to bring the prices of medical services and procedures into the open and to make those prices easily accessible to our patients—in short, to replace price opacity with price transparency.

Regarding Quality. We counsel that the Departments, in addressing the question of quality, whether by a forum or some other means, seek input from a range of stakeholders, and most particularly from patients and physicians. The Departments must be acutely conscious of the interests and agendas that inform what stakeholders have to say. The Departments should also never lose sight of the inescapable reality that any regulatory mandates on information-gathering that can be predicted to add to the administrative overhead already encumbering the practice of medicine in the United States will be at odds with efforts to create a freer, more-competitive marketplace in which prices can be first be expected to stop rising, and then proceed to fall.

Lastly, PPA calls for transparency in the level of the training attained by those who deliver care.